05.02.19

New Mobile Platform Records Patient Outcomes After Cataract Surgery

Source: Rayner

Rayner has developed RayPRO, a mobile phone and web-based app for collecting patient-reported outcomes (PROs) for 3 years after surgery. The company says this is the first time such software has been available for free to ophthalmic surgeons.

It is a bespoke platform that has been specifically developed to record outcomes after cataract surgery, gathering information on patient satisfaction and visual outcomes with the potential for quality improvement and complying with new legislation on medical devices. RayPRO is free to all Rayner IOL users and provides surgeons with feedback on surgery in real time. RayPRO can also be used to support surgeons’ recertification and audit requirements or even promote their surgical services to new patients.

It is the world’s first patient outcomes smartphone app for cataract surgeons, who register their consenting patients at the time of surgery. Patients are asked to record their levels of satisfaction within the first week of surgery in relation to the surgeon and the hospital where the surgery was performed. Then at 3 months, patients are prompted to rate their overall satisfaction with their surgery, record how often they wear glasses and for what type of activity; whether they have the visual outcomes they discussed with the surgeon. At 12 months, the patient is asked to score their overall satisfaction with the outcome of the surgery and if they experience any visual disturbances during the day or night and if they have had any additional eye procedures. Patients are asked again about additional eye procedures at 24 months and 36 months.

RayPRO will officially launch at the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting in San Diego, which takes place during 3-7 May, 2019. RayPRO will be available in Android and Apple versions and through web browsers, with patient questionnaires available in English, French, German, Italian, Spanish and Portuguese. Interested users are able to sign up now on the website www.rayner.com/raypro.

All information is anonymous, aggregated and completely private to the surgeon – no one else can access the personal data held about the patient or the surgeon. To support increasing medical device legislation Rayner will have access to aggregated data and trends at a global, country and hospital level.

With 27 million cataract surgeries worldwide each year, RayPRO has the potential to recruit hundreds of thousands of patients in real-time for research purposes, enabling deep data-driven insights into surgical and product performance and trends.

“Speaking with surgeons, their number one goal is always patient outcome; however, keeping on top of this metric for three years can be a challenge,” Tim Clover, Rayner CEO, said in a company news release. “As consumers, we’ve become accustomed to accessing key information instantaneously day or night on our smartphones. Being able to offer surgeons the same service for surgical outcomes is the driver behind RayPRO. We have found that patients are extremely keen to share feedback on such life-changing surgery and now it can be recorded in one place. With the scale of cataract surgery, we believe that the current practice of clinical studies covering 50 to 100 patients is just not sufficient to base decisions on; that’s why we want to offer every Rayner IOL with up to three years of patient data – free of charge. We want to be the IOL partner of choice for cataract surgeons all over the world.”

Professor Brian Little, former Director of Training in the Cataract Service at Moorfields Eye Hospital said: “The service that surgeons provide to patients is under increasing scrutiny. Collecting this data takes time, and perfect visual outcomes on paper do not always translate to patient satisfaction. RayPRO is an easy-to-use tool that will supplement our existing visual outcomes data with subjective patient feedback.”

Daniel Peek, Rayner Head of Regulatory Affairs, said: “Patient safety and device efficacy are paramount concerns at Rayner. All our medical devices are exhaustively tested before launching onto market and we can now focus the same level of attention and care on researching how devices perform in the real world after launch, beyond the laboratory and factory. Which is why we created RayPRO, a dedicated tool to allow every patient given a Rayner lens to let us know directly what their experience was and whether they are happy with their vision after their implant. By developing RayPRO, Rayner aim to have the most complete and comprehensive data of any IOL manufacturer, helping to make sure that we provide the best possible devices to surgeons and patients around the world.”

Rayner expect to have the first set of significant data and insights at 3 months, which will be  presented at the 37th annual congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Paris in September 2019.

 

Related Content